ASX-listed medical technology company, Proteomics International Laboratories, has entered into an agreement with Medical Horizons that will see the Italy-based group distribute the easy-to-use immunoassay version of Proteomics’ PromarkerD predictive test for diabetic kidney disease in Italy.
16/10/2020 - 13:27
Proteomics strikes kidney disease test deal in Italy
By Matt Birney
16/10/2020 - 13:27
Related Data & Insights
-
Proteomics International LaboratoriesClosing price for the last 90 trading daysPowered by Morningstar ®
-
Rank Company Revenue 136th Proteomics International Laboratories $3.2m 146th BauMart Holdings $2.2m 147th Carnegie Clean Energy $2.2m 149th icetana $1.9m 150th Sprintex $1.9m 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
16 Nov 2021
Board Moves November 16, 2021
03 Nov 2021
Manufacturing grants for medical innovations
26 Oct 2021
Board Moves October 26, 2021
11 Aug 2021
Proteomics to co-develop endometriosis test
11 Jun 2021
Appointments June 11, 2021
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX